Polk Wagner of the Law School spoke about the possibility of competition between foreign and domestic medical manufacturers enabled by waived COVID-19 patents. “My view is that it is extremely unlikely in the current set of circumstances that it will have a lot of impact on these vaccine companies. For one thing, they are already being paid enormous sums by most of the wealthy countries, anyway,” he said.
https://www.washingtonpost.com/business/2021/05/06/vaccine-patent-waiver-global-supply/ The Washington Post